Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
xylo+dex · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| xylo+dex nasal spray (0.1 mg+5 mg/dose) | EXPERIMENTAL | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
| Nasic | ACTIVE_COMPARATOR | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
| Name | Type | Description |
|---|---|---|
| xylo+dex nasal spray (0.1 mg+5 mg/dose) | DRUG | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
| Nasic | DRUG | Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days. |
Inclusion Criteria * Subjects of 18 years of age or older; * Subjects suffering from nasal congestion with a clinical diagnosis of acute upper respiratory tract infection where symptoms of nasal congestion have persisted for minimum of 3 hours and maximum of 36 hours; * Body mass index (BMI) 18.5 t...
xylo+dex is an investigational small molecule nasal spray being developed for the treatment of nasal congestion. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug combines xylometazoline and dexpanthenol in a single formulation.
xylo+dex contains xylometazoline, a decongestant that works by constricting blood vessels in the nasal passages, and dexpanthenol, which is believed to support mucosal healing. The combination is designed to relieve nasal congestion while potentially aiding tissue recovery.
xylo+dex is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 3 clinical development for nasal congestion.
xylo+dex is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of nasal congestion in adult patients.
xylo+dex has one completed Phase 3 clinical trial, NCT03439436, which compared two formulations of xylometazoline/dexpanthenol nasal spray for treating nasal congestion. The randomized, double-blind, active-controlled study enrolled 140 participants in Russia and has been completed.